Member Info for CHELSEA7

3k

Sells 54k

Buys 526k

6.93 Paid

18k

6.30/7 +6.40%

6.20/7 +5.60%

After 11.30 yesterday the volumes really started, getting larger nearing 1.00

6.80

TICK UP 6.20/7............Here we go

I believe so LL, just CNKS at 6.50 between us and a few others MMs on 7p

We know about the new Southampton building and I popped in to the UCLH NEW BUILDING yesterday specialising in Blood Cancers, Immunology and Tropical Diseases. Tremendous facilities.

21/07/2020 08:24 87,406 6.4

MMs taking 230k+ 6.305.....................1 MM

7 trades......................All buys

6.20/6.50

6.45 Paid Again

Just 2 MMs on Ask was 5/6 this morning.

GF, yesterdays volumes.............................

CHELSEA7 Premium Member

Posts: 41,015

Price: 6.25

Strong Buy

Volume 3.234mMon 18:48
Buys 2.65m

Sells 634k

Back to 60 Trades today,

For 100k

For 43k and 17k

Tick ups being lined up on level 2

For another 25k at 6.325

Great find Bermuda

For 25k..........................Good Morning

The ability to increase the potential therapeutic properties of any antibody would therefore be seen as highly advantageous. Scancell has used its AvidiMab™ technology to increase the avidity of its TaG antibodies, and these are currently being evaluated for the treatment of cancer. They are also being developed as antibody-drug conjugates (ADC).3



Professor Lindy Durrant, Chief Scientific Officer of Scancell and Corresponding Author, commented:



"We are pleased to have our work published in the prestigious, peer reviewed journal, Cancer Research. Our AvidiMab™ technology increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification also causes direct killing of cancer cells by our glycan targeting antibodies, and therefore we believe this technology has the ability to create superior candidates for cancer immunotherapy."

Sounds good to me!! GN